SS
CMMB

SBI Securities’s Chemomab Therapeutics CMMB Stock Holding History

SBI Securities’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55 Buy
34
+6
+21% +$10 ﹤0.01% 3642
2026
Q1 		$44 Buy
28
+2
+8% +$3 ﹤0.01% 3602
2025
Q4 		$43 Hold
26
– – ﹤0.01% 3603
2025
Q3 		$68 Sell
26
-2
-7% -$7 ﹤0.01% 3626
2025
Q2 		$129 Buy
28
+2
+8% +$10 ﹤0.01% 3454
2025
Q1 		$113 Buy
26
+1
+4% +$7 ﹤0.01% 3402
2024
Q4 		$181 Buy
+25
New +$158 ﹤0.01% 3274

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities's CMMB Position: Q2 2026 in Review

SBI Securities increased its Chemomab Therapeutics (CMMB) stake by 21% in Q2 2026, buying an estimated $10 and bringing the position to 34 shares worth $55. The position accounts for ﹤0.01% of the portfolio, ranked #3642.

SBI Securities first reported a position in CMMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $181 in Q4 2024. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • SBI Securities held 34 shares of Chemomab Therapeutics worth $55 as of Q2 2026.
  • SBI Securities bought 6 Chemomab Therapeutics shares in Q2 2026, an estimated $10.
  • Chemomab Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3642 holding.
  • SBI Securities first reported a position in Chemomab Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Chemomab Therapeutics position peaked at $181 in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.